SymBio Pharmaceuticals (4582) - New formulations extend Treakisym patent life
Edison Investment Research - Pharmaceutical & healthcare - SymBio Pharmaceuticals: SymBio has substantially increased the value of its Treakisym franchise through in-licencing novel bendamustine formulations from Eagle Pharmaceuticals for $12.5m. The new formulations bring a lower cost of goods and 10 years of additional patent protection to help in life cycle management of the Treakisym franchise. Sales of Treakisym following the approval of two new indications in 2016 have exceeded the company’s expectations, leading it to upgrade FY17 sales guidance. Interim data from the global Phase III rigosertib trial could become available during Q417. We value SymBio at ¥19.7bn (unchanged), with the enhanced Treakisym portfolio offsetting the suspension of IONSYS development.
ISIN: JP3383050006
Original Article: SymBio Pharmaceuticals (4582) - New formulations extend Treakisym patent life
